A5114376695- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Melanoma and MAPK Pathways
- Ear and Head Tumors
- Cancer Immunotherapy and Biomarkers
- Head and Neck Surgical Oncology
- Cutaneous Melanoma Detection and Management
- Hematological disorders and diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Neutropenia and Cancer Infections
- Genomics and Rare Diseases
- HER2/EGFR in Cancer Research
- Radiopharmaceutical Chemistry and Applications
- Pharmacological Effects of Natural Compounds
- Metal complexes synthesis and properties
- Blood disorders and treatments
- PI3K/AKT/mTOR signaling in cancer
Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno
2001-2021
Centro Científico Tecnológico - San Juan
2020
Institut Gustave Roussy
1989-1995
The University of Texas MD Anderson Cancer Center
1994
Laboratoire d'études sur les monothéismes
1989
BackgroundAfatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade afatinib plus paclitaxel superior outcomes versus switching to chemotherapy alone acquiring resistance erlotinib/gefitinib and monotherapy.Patients methodsPatients relapsed/refractory disease following ≥1 line of chemotherapy, whose tumors had progressed...
Pretherapeutic identification of patients likely to benefit from neoadjuvant chemotherapy for head and neck epidermoid cancer is interest. We retrospectively analyzed the pretherapeutic computed tomographic (CT) scans lymph nodes 70 with cancer. All were clinically classified as having stage IV disease. The purpose our analysis was compare prognostic value CT node density that following factors: age, T N categories, Eastern Cooperative Oncology Group performance status, tumor site,...
BRCA1/2 mutations in Latin America are scarcely documented and serious need of knowledge about the spectrum BRCA pathogenic variants, information which may alter clinical practice subsequently improve patient outcome. In addition, search for data on testing policies different regions constitutes a fundamental strength present study, analyzes gene sequences large rearrangements 940 probands with familial and/or personal history breast/ovary cancer (BOC). non-mutated DNA samples, Multiplex...
<b><i>Objective:</i></b> Latin American countries are heterogeneous in terms of lung cancer incidence and exposure to potential carcinogens. We evaluated the frequency clinical characteristics <i>ALK</i> rearrangements (<i>ALKr</i>) America. <b><i>Methods:</i></b> A total 5,130 patients from 10 were screened for inclusion. <i>ALKr</i> detection was performed by fluorescence situ hybridization (FISH),...
One hundred two patients with recurrent and/or metastatic head and neck squamous cell cancer were entered into four consecutive phase II trials, all cisplatinum (C-DDP, 100 mg/m2/cycle)-based. The combinations tried C-DDP, bleomycin, fluorouracil (CFB) on 54 patients, vindesin in 36 (CV). CFB combination was given C-DDP by continuous infusion over 96 hours (23 patients) or day 1 (31 patients). CV regimen also different schedules, VDS at 3 mg/m2/g weekly (12 a 96-hour (0.6 to 1.0 mg/m2/d) 24...
Lung cancer is a leading cause of cancer-related deaths in Latin America, with non-small cell lung (NSCLC) being the most prevalent. The current study aimed to report real-world data on epidermal growth factor receptor (EGFR) mutational testing and treatment regimens at diagnosis progression patients metastatic NSCLC across four American countries (Argentina, Chile, Colombia Uruguay). A retrospective, multicenter, observational was conducted using medical records from participating...
PURPOSE To evaluate an intensive concomitant chemoradiotherapy protocol of conventional radiotherapy with intermittent cisplatin (CDDP) and continuous-infusion fluorouracil (5-FU) in unresectable, locally advanced squamous cell carcinoma the head neck (SCCHN). PATIENTS AND METHODS Fifty-seven patients unresectable stage IV MO disease (International Union Against Cancer [UICC]/American Joint Committee on [AJCC], 1987) received 70 Gy followed by CDDP 80 mg/m2 5-FU 300 mg/m2/d. Response was...
Lung cancer is the leading cause of cancer-related death worldwide. Recent advances in management non-small cell carcinoma are focused on discovery targeted therapies and novel immunotherapy strategies for patients with advanced disease. Treatment anti PD-(L)1 immune checkpoint inhibitors requires development predictive biomarkers to select those that can most benefit from these therapies. Several immunohistochemical have been developed different technological platforms. However, useful...
A Phase II study of cisplatin (100 mg/m2 on day 1 and bleomycin (15 mg intravenous push 1) followed by 5 days continuous infusions 5-fluorouracil (5-FU) (650 mg/m2/d) (16 repeated at 21-day intervals was performed in 54 previously untreated patients with nonmetastatic (MO), locoregionally advanced head neck squamous cell carcinoma (SCC). The aim this to increase the complete response rate chemotherapy identify prognostic factors that may influence local control disease-free survival. From...
5-Fluorouracil (5-FU) and bleomycin (BLM) are active agents in head neck squamous-cell cancer (H-N-scc). Less toxicity an enhanced activity have been reported when these administered by continuous infusion (CI), with or without a bolus of cisplatin (CDDP), another agent. Thirty-three patients recurrent and/or metastatic squamous cell carcinoma were treated combination regimen including CDDP (100 mg/m2) on day 1 plus BLM (15-mg followed 16 mg/m2/day CI) 5-FU (650 days 1-5 every 3 weeks....
The chemotherapeutic treatment of recurrent and/or metastatic squamous cell carcinoma (SCC) the head and neck (H & N) has a very dismal prognosis, with survival usually not exceeding 1 year. Reported objective response rates vary between 3% 70%. This difference appears largely attributable to heterogeneity patient populations included in most published Phase II studies H N cancer. They include together initially metastatic, recurrent, post primary disease patients. These patients respond...